{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:45:59Z","timestamp":1792251959496,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xi\u2018an Science and Technology Research and Development Program, Shaanxi Province,China","award":["23YXYJ0143"],"award-info":[{"award-number":["23YXYJ0143"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The vancomycin dosing regimen for neonates is primarily determined by gestational age (GA) and postnatal age(PNA). Nonetheless, initial trough concentrations frequently fall below therapeutic levels in neonates administered vancomycin. This study seeks to examine the relationship between vancomycin trough concentrations and gestational age in neonates, thereby offering a reference for individualized vancomycin dosing tailored to neonates of varying gestational ages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was undertaken to collect clinical data on neonates treated with vancomycin and subjected to trough concentration monitoring in the Neonatal Intensive Care Unit (NICU) at Northwest Women\u2019s and Children\u2019s Hospital over the preceding six years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Utilizing a two-piecewise linear regression model, the P-value for the log-likelihood ratio was 0.007, indicating statistical significance, and an inflection point was identified at 34.6 weeks(approximately 242 days). For gestational ages less than 34.6 weeks, a positive correlation was observed between GA and the initial vancomycin trough concentration (TCV) (\u03b2\u2009=\u20090.08, 95% CI: 0.01, 0.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021). Conversely, for gestational ages exceeding 34.6 weeks, a negative trend of borderline significance (\u03b2 = -0.10, 95% CI: -0.20 to 0.00,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.059).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vancomycin trough concentrations in neonates exhibit a significant correlation with GA. This retrospective study, conducted at a single center, revealed a non-linear relationship between gestational age and initial vancomycin trough concentrations in neonates, identifying an inflection point at approximately 34.6 weeks. The results indicate that existing gestational age-based dosing protocols may inadequately account for pharmacokinetic transitions, underscoring the necessity for prospective studies to validate therapeutic drug monitoring protocols stratified by gestational age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-026-07630-8","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:54:21Z","timestamp":1788483261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between vancomycin trough concentration monitoring and gestational age in neonates: a single-center, retrospective observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanglu","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"11","key":"7630_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Ph. 2020;77(11):835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","journal-title":"Am J Health-Syst Ph"},{"issue":"11","key":"7630_CR2","doi-asserted-by":"publisher","first-page":"e022603","DOI":"10.1136\/bmjopen-2018-022603","volume":"8","author":"A Gwee","year":"2018","unstructured":"Gwee A, Cranswick N, Donath SM, Hunt R, Curtis N. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: the VANC trial. BMJ Open. 2018;8(11):e022603. https:\/\/doi.org\/10.1136\/bmjopen-2018-022603.","journal-title":"BMJ Open"},{"issue":"1","key":"7630_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/ejhpharm-2019-002181","volume":"29","author":"TH Dawoud","year":"2022","unstructured":"Dawoud TH, Khan N, Afzal U, Varghese N, Rahmani A, Abu-Sa\u2019Da O. Assessment of initial vancomycin trough levels and risk factors of vancomycin-induced nephrotoxicity in neonates. Eur J Hosp Pharm. 2022;29(1):44\u20139. https:\/\/doi.org\/10.1136\/ejhpharm-2019-002181.","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"7630_CR4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1248\/bpb.b19-01003","volume":"43","author":"M Kondo","year":"2020","unstructured":"Kondo M, Nakagawa S, Orii S, et al. Association of initial trough concentrations of vancomycin with outcomes in pediatric patients with gram-positive bacterial infection. Biol Pharm Bull. 2020;43(10):1463\u20138. https:\/\/doi.org\/10.1248\/bpb.b19-01003.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"7630_CR5","doi-asserted-by":"publisher","first-page":"F221","DOI":"10.1136\/fn.81.3.f221","volume":"81","author":"C Grimsley","year":"1999","unstructured":"Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81(3):F221\u20137. https:\/\/doi.org\/10.1136\/fn.81.3.f221 . PMID: 10525029; PMCID: PMC1721000.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"7630_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1128\/AAC.48.4.1159-1167.2004","volume":"48","author":"T Kimura","year":"2004","unstructured":"Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48(4):1159\u201367. https:\/\/doi.org\/10.1128\/AAC.48.4.1159-1167.2004 . PMID: 15047516; PMCID: PMC375245.","journal-title":"Antimicrob Agents Chemother"},{"key":"7630_CR7","doi-asserted-by":"publisher","unstructured":"Frattarelli DA, Ergun H, Lulic-Botica M, Lehr VT, Aranda JV. Vancomycin elimination in human infants with intrauterine growth retardation. Pediatr Infect Dis J. 2005;24(11):979\u201383. https:\/\/doi.org\/10.1097\/01.inf.0000186283.95728.34. PMID: 16282933.","DOI":"10.1097\/01.inf.0000186283.95728.34"},{"key":"7630_CR8","doi-asserted-by":"publisher","unstructured":"Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, Kildoo C, Connor JD. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41(9):927\u201334. https:\/\/doi.org\/10.1177\/00912700122010898. PMID: 11549096.","DOI":"10.1177\/00912700122010898"},{"key":"7630_CR9","doi-asserted-by":"publisher","first-page":"104278","DOI":"10.1016\/j.phrs.2019.104278","volume":"154","author":"K Dao","year":"2020","unstructured":"Dao K, Guidi M, Andr\u00e9 P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacol Res. 2020;154:104278. https:\/\/doi.org\/10.1016\/j.phrs.2019.104278.","journal-title":"Pharmacol Res"},{"key":"7630_CR10","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1038\/s41598-021-85529-3","volume":"11","author":"SM Lee","year":"2021","unstructured":"Lee SM, Yang S, Kang S, Chang MJ. Population pharmacokinetics and dose optimization of vancomycin in neonates. Sci Rep. 2021;11:6168. https:\/\/doi.org\/10.1038\/s41598-021-85529-3.","journal-title":"Sci Rep"},{"issue":"Suppl 4","key":"7630_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1203\/00006450-199704001-00337","volume":"41","author":"WD Engle","year":"1997","unstructured":"Engle WD, Gard JW, Tsui JK. Importance of postnatal age (PNA) in vancomycin pharmacokinetics in the critically-ill neonate. Pediatr Res. 1997;41(Suppl 4):55. https:\/\/doi.org\/10.1203\/00006450-199704001-00337.","journal-title":"Pediatr Res"},{"issue":"1","key":"7630_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","volume":"63","author":"BJ Anderson","year":"2007","unstructured":"Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63(1):75\u201384. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02725.x . Epub 2006 Jul 21.","journal-title":"Br J Clin Pharmacol"},{"issue":"29","key":"7630_CR13","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.6039\/j.issn.1001-0408.2016.29.10","volume":"27","author":"C Tao Xingru","year":"2016","unstructured":"Tao Xingru C. Analysis of influencing factors of vancomycin blood concentration in neonates. China Pharm. 2016;27(29):4067\u20139. https:\/\/doi.org\/10.6039\/j.issn.1001-0408.2016.29.10.","journal-title":"China Pharm"},{"issue":"3","key":"7630_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mpaic.2010.12.001","volume":"12","author":"A Skinner","year":"2011","unstructured":"Skinner A. Neonatal pharmacology. Anaest intens care M. 2011;12(3):79\u201384. https:\/\/doi.org\/10.1016\/j.mpaic.2010.12.001.","journal-title":"ANAEST INTENS CARE M"},{"key":"7630_CR15","doi-asserted-by":"publisher","unstructured":"Allegaert K, Anderson BJ, van den Anker JN, Vanhaesebrouck S, de Zegher F. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29(3):284\u201391. https:\/\/doi.org\/10.1097\/FTD.0b013e31806db3f5. PMID: 17529884.","DOI":"10.1097\/FTD.0b013e31806db3f5"},{"key":"7630_CR16","doi-asserted-by":"publisher","unstructured":"Coulthard MG. Maturation of glomerular filtration in preterm and mature babies. Early Hum Dev. 1985;11(3\u20134):281\u201392. https:\/\/doi.org\/10.1016\/0378-3782(85)90082-9. PMID: 4054047.","DOI":"10.1016\/0378-3782(85)90082-9"},{"issue":"3","key":"7630_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jac\/dkab469","volume":"77","author":"A Gwee","year":"2022","unstructured":"Gwee A, Duffull SB, Daley AJ, et al. Identifying a therapeutic target for vancomycin against staphylococci in young infants. J Antimicrob Chemother. 2022;77(3):704\u201310. https:\/\/doi.org\/10.1093\/jac\/dkab469.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"7630_CR18","doi-asserted-by":"publisher","first-page":"e02193","DOI":"10.1128\/AAC.02193-17","volume":"62","author":"A Frymoyer","year":"2018","unstructured":"Frymoyer A, Hersh AL, Benet LZ, et al. Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2018;62(4):e02193\u201317. https:\/\/doi.org\/10.1128\/AAC.02193-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"7630_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40121-015-0074-5","volume":"4","author":"C Stockmann","year":"2015","unstructured":"Stockmann C, Hersh AL, Roberts JK, et al. External validation of a neonatal vancomycin dosing calculator. Infect Dis Ther. 2015;4(2):155\u201364. https:\/\/doi.org\/10.1007\/s40121-015-0074-5.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"7630_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00228-018-2450-7","volume":"74","author":"C Chen","year":"2018","unstructured":"Chen C, Tang H, Hu Y, et al. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 2018;74(6):733\u201342. https:\/\/doi.org\/10.1007\/s00228-018-2450-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"7630_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.5863\/1551-6776-25.9.730","volume":"25","author":"JT Pham","year":"2020","unstructured":"Pham JT, O\u2019Connor M, Yu C, et al. Challenges of vancomycin dosing and therapeutic drug monitoring in pediatrics: a review. J Pediatr Pharmacol Ther. 2020;25(9):730\u201341. https:\/\/doi.org\/10.5863\/1551-6776-25.9.730.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"7630_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bcp.13842","volume":"85","author":"A Smits","year":"2019","unstructured":"Smits A, De Cock RF, Allegaert K, et al. Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates. Br J Clin Pharmacol. 2019;85(4):865\u201373. https:\/\/doi.org\/10.1111\/bcp.13842.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"7630_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.pedneo.2021.11.010","volume":"63","author":"Q Chen","year":"2022","unstructured":"Chen Q, Wan J, Shen W, et al. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records. Pediatr Neonatol. 2022;63(3):247\u201354. https:\/\/doi.org\/10.1016\/j.pedneo.2021.11.010.","journal-title":"Pediatr Neonatol"},{"issue":"6","key":"7630_CR24","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/jac\/dkaf112","volume":"80","author":"AL Wilkins","year":"2025","unstructured":"Wilkins AL, Yang W, Duffull SB, Cranswick N, Curtis N, Zhu X, Gwee A. Evaluation of an optimized intermittent vancomycin dosing regimen in infants. J Antimicrob Chemother. 2025;80(6):1635\u20139. https:\/\/doi.org\/10.1093\/jac\/dkaf112.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"7630_CR25","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1093\/jac\/dku239","volume":"69","author":"M de Hoog","year":"2014","unstructured":"de Hoog M, Mouton JW, van den Anker JN. Prospective validation of neonatal vancomycin dosing regimens. J Antimicrob Chemother. 2014;69(11):3007\u201314. https:\/\/doi.org\/10.1093\/jac\/dku239.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07630-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07630-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07630-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:04:14Z","timestamp":1792249454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07630-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7630"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-07630-8","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the full official name: Medical Ethics Committee of Northwest Women\u2019s and Children\u2019s Hospital (Ethics approval No. 2023010). Importantly, the requirement for written informed consent to participate was formally waived by this ethics committee. The waiver was granted because this is a retrospective observational study using only fully de-identified clinical data, and no direct clinical interventions were performed on enrolled neonates. All procedures in this research strictly abide by the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable. No identifiable patient images or personal clinical information are published within this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1015"}}